Noninferiority on Overall Survival of Every-2-Weeks vs Weekly Schedule of Cetuximab for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer

被引：0

作者：

Kasper-Virchow, Stefan ^{[1
]}

Cheng, Ann-Lll ^{[2
]}

Overkamp, Friedrich ^{[3
]}

Rouyer, Magali ^{[4
]}

Foch, Caroline ^{[5
]}

Lamy, Francois-Xavier ^{[5
]}

Esser, Regina ^{[5
]}

Messinger, Diethelm ^{[6
]}

Rothe, Vivien ^{[6
]}

Chen, Wenfeng ^{[7
]}

Brodowicz, Thomas ^{[8
]}

Zielinski, Christoph ^{[9
,10
]}

机构：

[1] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[2] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[3] Oncologianova GmbH, Recklinghausen, Germany

[4] Univ Bordeaux, INSERM, CIC 1401, Bordeaux Pharmacoepi BPE, Bordeaux, France

[5] Merck KGaA, Darmstadt, Germany

[6] Prometris GmbH, Mannheim, Germany

[7] Merck Serono, Shanghai, Peoples R China

[8] Med Univ Vienna, Dept Med Oncol, Gen Hosp, Internal Med, Vienna, Austria

[9] Vienna Gen Hosp, Vienna, Austria

[10] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1019

引用

页码：219 / 220

页数：2

共 50 条

[31] CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER [J].

Ubago, R. ;

Castillo, M. A. ;

Flores, S. ;

Rodriguez, R. ;

Beltran, C. .

VALUE IN HEALTH, 2011, 14 (07) :A433-A434

[32] Cetuximab for the first-line treatment of metastatic colorectal cancer [J].

Meads, C. ;

Round, J. ;

Tubeuf, S. ;

Moore, D. ;

Pennant, M. ;

Baylis, S. .

HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 :1-8

[33] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer [J].

Zekri, Jamal ;

Baghdadi, Mohammed Abbas ;

Ibrahim, Refaei Belal ;

Meliti, Abdelrazak ;

Sobahy, Turki M. .

ECANCERMEDICALSCIENCE, 2022, 16 :1-16

[34] Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study [J].

Cheng, Ann-Lii ;

Cornelio, Gerardo ;

Shen, Lin ;

Price, Timothy ;

Yang, Tsai-Sheng ;

Chung, Ik Joo ;

Dai, Guang-Hai ;

Lin, Jen-Kou ;

Sharma, Atul ;

Yeh, Kun-Huei ;

Ma, Brigette ;

Zaatar, Adel ;

Guan, Zhongzhen ;

Masood, Nehal ;

Srimuninnimit, Vichien ;

Yau, Thomas ;

Gibbs, Peter ;

Wang, Xiuwen ;

Doval, Dinesh Chandra ;

Oh, Seung-Taek ;

Shim, Byoung Yong ;

Gorospe, Charity ;

Wang, Hwei-Ming ;

Sirachainan, Ekaphop ;

Hill, Andrew ;

Suh, Kwang Wook ;

Beier, Frank ;

Chatterjee, Sudipto ;

Lim, Robert .

CLINICAL COLORECTAL CANCER, 2017, 16 (02) :E73-E88

[35] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer [J].

Ohta, Katsuya ;

Ikenaga, Masakazu ;

Uemura, Mamoru ;

Sakata, Kazuya ;

Nishimura, Junichi ;

Hata, Taishi ;

Matsuda, Chu ;

Mizushima, Tsunekazu ;

Doki, Yuichiro ;

Mori, Masaki .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 :216-216

[36] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer [J].

Uemura, Mamoru ;

Kim, Ho Min ;

Hata, Tsuyoshi ;

Sakata, Kazuya ;

Okuyama, Masaki ;

Takemoto, Hiroyoshi ;

Fujii, Hitoshi ;

Fukuzaki, Takayuki ;

Morita, Tetsushi ;

Hata, Taishi ;

Takemasa, Ichiro ;

Satoh, Taroh ;

Mizushima, Tsunekazu ;

Doki, Yuichiro ;

Mori, Maski .

MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) :375-379

[37] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study [J].

Shigenori Kadowaki ;

Toshiki Masuishi ;

Takashi Ura ;

Keiji Sugiyama ;

Seiichiro Mitani ;

Yukiya Narita ;

Hiroya Taniguchi ;

Kei Muro .

International Journal of Clinical Oncology, 2021, 26 :701-707

[38] Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan [J].

Chen, C-C. ;

Chang, S-C. ;

Chang, Y-Y. ;

Lin, B-W. ;

Chen, H. ;

Hsieh, Y-Y. ;

Hsu, H-C. ;

Hsieh, M-C. ;

Kuan, F-C. ;

Wu, C. C. ;

Lu, W-C. ;

Su, Y-L. ;

Liang, Y-H. ;

Chen, C. ;

Huang, S-Y. ;

Wang, C. Y. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S722-S722

[39] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial [J].

Wang, Huijuan ;

Huang, Lingfei ;

Gao, Peng ;

Zhu, Zhengyi ;

Ye, Weifeng ;

Ding, Haiying ;

Fang, Luo .

BMJ OPEN, 2020, 10 (02)

[40] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study [J].

Kadowaki, Shigenori ;

Masuishi, Toshiki ;

Ura, Takashi ;

Sugiyama, Keiji ;

Mitani, Seiichiro ;

Narita, Yukiya ;

Taniguchi, Hiroya ;

Muro, Kei .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) :701-707

← 1 2 3 4 5 →